(Q34979868)

5 August 2017

1 reference

title

The challenge of developing a vaccine against hepatitis C virus (English)

1 reference

5 August 2017

1 reference

0 references

1 reference

Jens Bukh

2

0 references

Robert H. Purcell

series ordinal

3

object named as

Robert H Purcell

1 reference

5 August 2017

Xavier Forns

1

1 reference

5 August 2017

1 November 2002

1 reference

5 August 2017

Journal of Hepatology

1 reference

5 August 2017

37

1 reference

5 August 2017

5

1 reference

5 August 2017

684-695

1 reference

Toward a surrogate model for hepatitis C virus: An infectious molecular clone of the GB virus-B hepatitis agent.

5 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Isolation of novel virus-like sequences associated with human hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Epidemiology of hepatitis C in the United States.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Natural history of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Lack of Protective Immunity Against Reinfection with Hepatitis C Virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Immunity in hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Quasispecies in viral persistence and pathogenesis of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Evolution of the E2 region of hepatitis C virus in an infant infected by mother-to-infant transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Long-term follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Transcripts of a chimeric cDNA clone of hepatitis C virus genotype 1b are infectious in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Hepatitis C virus: an infectious molecular clone of a second major genotype (2a) and lack of viability of intertypic 1a and 2a chimeras

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Early antibody response against hypervariable region 1 is associated with acute self-limiting infections of hepatitis C virus.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Patients infected with the same hepatitis C virus strain display different kinetics of the isolate-specific antibody response.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Long-term outcome of chronic hepatitis C virus infection in primary hypogammaglobulinaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Vaccine development for hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Perspectives for a vaccine against hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Determinants of viral clearance and persistence during acute hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

T-lymphocyte response to hepatitis C virus in different clinical courses of infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Analysis of a successful immune response against hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Previously Infected and Recovered Chimpanzees Exhibit Rapid Responses That Control Hepatitis C Virus Replication upon Rechallenge

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Novel cell culture systems for the hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Binding of hepatitis C virus to CD81

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Cell fusion activity of hepatitis C virus envelope proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Prospects for vaccine protection against HIV-1 infection and AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Persistent and transient replication of full-length hepatitis C virus genomes in cell culture

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

In vivo analysis of the 3' untranslated region of the hepatitis C virus after in vitro mutagenesis of an infectious cDNA clone

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Vaccination of chimpanzees against infection by the hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Hepatitis C virus structural proteins assemble into viruslike particles in insect cells

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Hepatitis C virus-like particles synthesized in insect cells as a potential vaccine candidate

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Gene vaccination: plasmid DNA is more than just a blueprint

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

DNA immunization of mice and macaques with plasmids encoding hepatitis C virus envelope E2 protein expressed intracellularly and on the cell surface.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Plasmid DNA-based immunization for hepatitis C virus structural proteins: immune responses in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Modulation of immune responses to hepatitis C virus envelope E2 protein following injection of plasmid DNA using single or combined delivery routes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Expression of noncovalent hepatitis C virus envelope E1-E2 complexes is not required for the induction of antibodies with neutralizing properties following DNA immunization.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Characterization of modified hepatitis C virus E2 proteins expressed on the cell surface.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

DNA vaccine strategies for hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Induction of hepatitis C virus E1 envelope protein-specific immune response can be enhanced by mutation of N-glycosylation sites

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Plasmid DNA expressing a secreted or a nonsecreted form of hepatitis C virus nucleocapsid: comparative studies of antibody and T-helper responses following genetic immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Hepatitis viruses and signal transduction: true to the core?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Enhanced cellular immunity to hepatitis C virus nonstructural proteins by codelivery of granulocyte macrophage-colony stimulating factor gene in intramuscular DNA immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

DNA-based vaccination against hepatitis C virus (HCV): effect of expressing different forms of HCV E2 protein and use of CpG-optimized vectors in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Uptake and adjuvant activity of orally delivered saponin and ISCOM vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Induction of antibodies against structural proteins of hepatitis C virus in mice using recombinant adenovirus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Alphavirus-based expression vectors: strategies and applications

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Hepatitis C virus non-structural protein 3-specific cellular immune responses following single or combined immunization with DNA or recombinant Semliki Forest virus particles

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

DNA prime-canarypox boost with polycistronic hepatitis C virus (HCV) genes generates potent immune responses to HCV structural and nonstructural proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Characterization of vesicular stomatitis virus recombinants that express and incorporate high levels of hepatitis C virus glycoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Recent advances with recombinant bacterial vaccine vectors.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Oral immunization with HCV-NS3-transformed Salmonella: induction of HCV-specific CTL in a transgenic mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Experimental vaccine activities of recombinant E1 and E2 glycoproteins and hypervariable region 1 peptides of hepatitis C virus in chimpanzees

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Towards a solution for hepatitis C virus hypervariability: mimotopes of the hypervariable region 1 can induce antibodies cross-reacting with a large number of viral variants

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

Monoclonal antibodies with broad specificity for hepatitis C virus hypervariable region 1 variants can recognize viral particles

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900308-2

7 January 2021

10.1016/S0168-8278(02)00308-2

Identifiers

DOI

1 reference

5 August 2017

1 reference

PubMed ID

12399239